BRPI0919937A2 - composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina - Google Patents

composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina

Info

Publication number
BRPI0919937A2
BRPI0919937A2 BRPI0919937A BRPI0919937A BRPI0919937A2 BR PI0919937 A2 BRPI0919937 A2 BR PI0919937A2 BR PI0919937 A BRPI0919937 A BR PI0919937A BR PI0919937 A BRPI0919937 A BR PI0919937A BR PI0919937 A2 BRPI0919937 A2 BR PI0919937A2
Authority
BR
Brazil
Prior art keywords
imidazoquinoline
enhancing
compound
adjuvant activity
adjuvant
Prior art date
Application number
BRPI0919937A
Other languages
English (en)
Inventor
David Johnson
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0919937A2 publication Critical patent/BRPI0919937A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0919937A 2008-10-24 2009-10-23 composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina BRPI0919937A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10821008P 2008-10-24 2008-10-24
US22422609P 2009-07-09 2009-07-09
US22993309P 2009-07-30 2009-07-30
PCT/US2009/061867 WO2010048520A1 (en) 2008-10-24 2009-10-23 Lipidated imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
BRPI0919937A2 true BRPI0919937A2 (pt) 2016-02-16

Family

ID=42119702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919937A BRPI0919937A2 (pt) 2008-10-24 2009-10-23 composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina

Country Status (23)

Country Link
US (2) US8624029B2 (pt)
EP (1) EP2341933B1 (pt)
JP (1) JP5695569B2 (pt)
KR (1) KR20110077004A (pt)
CN (1) CN102264394B (pt)
AU (1) AU2009308278B2 (pt)
BR (1) BRPI0919937A2 (pt)
CA (1) CA2741291A1 (pt)
CY (1) CY1119981T1 (pt)
DK (1) DK2341933T3 (pt)
ES (1) ES2656813T3 (pt)
HR (1) HRP20180063T1 (pt)
HU (1) HUE036531T2 (pt)
IL (1) IL212417A (pt)
LT (1) LT2341933T (pt)
MX (1) MX2011004249A (pt)
NO (1) NO2341933T3 (pt)
PL (1) PL2341933T3 (pt)
PT (1) PT2341933T (pt)
SI (1) SI2341933T1 (pt)
TR (1) TR201802083T4 (pt)
WO (1) WO2010048520A1 (pt)
ZA (1) ZA201103590B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2674170B1 (en) * 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
US20140242112A1 (en) * 2012-11-30 2014-08-28 Glaxosmithkline Biologicals S.A. Novel vaccine
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10471139B2 (en) * 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
ES2917887T3 (es) 2014-11-13 2022-07-12 Glaxosmithkline Biologicals Sa Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
CA2998995A1 (en) 2015-09-29 2017-04-06 Astrazeneca Aktiebolag Adenine conjugate compounds and their use as vaccine adjuvants
HUE055079T2 (hu) 2015-10-07 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Pirimidin vegyületek
EP3390416B1 (en) * 2015-12-14 2020-08-19 GlaxoSmithKline Biologicals S.A. Phospholipidation of imidazoquinolines and oxoadenines
JP2019500360A (ja) 2015-12-14 2019-01-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Tlr7及びtlr8アゴニストとしてのpeg化されたイミダゾキノリン
US9966457B2 (en) * 2016-03-18 2018-05-08 Globalfoundries Inc. Transistor structure with varied gate cross-sectional area
BE1024865B1 (fr) * 2016-09-07 2018-07-31 Glaxosmithkline Biologicals Sa Derives d'imidazoquinoleine
PL3603619T3 (pl) 2017-03-29 2025-11-17 Sumitomo Pharma Co., Ltd. Preparat adjuwantu szczepionkowego
RU2020124007A (ru) 2017-12-21 2022-01-21 Сумитомо Дайниппон Фарма Ко., Лтд. Комбинированный препарат, включающий агонист tlr7
AU2019311965B2 (en) 2018-07-23 2026-02-19 Japan Institute For Health Security Composition containing influenza vaccine
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
EP3972636A4 (en) 2019-05-23 2023-08-02 The University Of Montana VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2022076723A1 (en) * 2020-10-08 2022-04-14 Icahn School Of Medicine At Mount Sinai Imdq-peg-chol adjuvant and uses thereof
CN119320387B (zh) * 2024-12-19 2025-06-27 杭州天龙药业有限公司 基于Toll样受体激动剂的疫苗佐剂脂质化合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285420B6 (cs) * 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2004032829A2 (en) * 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
EP1617872A4 (en) 2003-04-10 2011-09-07 3M Innovative Properties Co METHOD AND COMPOSITIONS FOR IMPROVING THE IMMUNE RESPONSE
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US8871782B2 (en) * 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
CA2564855A1 (en) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
AU2005284835A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
US7998945B2 (en) * 2005-12-23 2011-08-16 Jado Technologies Gmbh Methods for the treatment and amelioration of atopic dermatitis

Also Published As

Publication number Publication date
JP2012506865A (ja) 2012-03-22
CY1119981T1 (el) 2018-12-12
MX2011004249A (es) 2011-07-20
IL212417A (en) 2017-01-31
EP2341933A1 (en) 2011-07-13
PT2341933T (pt) 2018-02-13
CN102264394A (zh) 2011-11-30
PL2341933T3 (pl) 2018-04-30
EP2341933B1 (en) 2017-11-22
ZA201103590B (en) 2012-10-31
US8946421B2 (en) 2015-02-03
TR201802083T4 (tr) 2018-03-21
IL212417A0 (en) 2011-06-30
US8624029B2 (en) 2014-01-07
AU2009308278A1 (en) 2010-04-29
LT2341933T (lt) 2018-04-10
KR20110077004A (ko) 2011-07-06
WO2010048520A1 (en) 2010-04-29
ES2656813T3 (es) 2018-02-28
NO2341933T3 (pt) 2018-04-21
CN102264394B (zh) 2014-01-01
HRP20180063T1 (hr) 2018-02-23
SI2341933T1 (en) 2018-03-30
DK2341933T3 (da) 2018-01-29
JP5695569B2 (ja) 2015-04-08
US20140323731A1 (en) 2014-10-30
HUE036531T2 (hu) 2018-07-30
EP2341933A4 (en) 2012-03-14
AU2009308278B2 (en) 2014-11-27
US20110282061A1 (en) 2011-11-17
CA2741291A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
BRPI0906906A2 (pt) Método para preparar um composto e composto
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BR112012002608A2 (pt) composição lubrificante, e, método para melhorar o desempenho de uma composição lubrificante.
BR112013007604A8 (pt) composto, composição, método para controlar um nematoide parasitário e semente tratada
BRPI0917714A2 (pt) método para preparar uma microesfera de liberação prolongada, e, microesfera de liberação prolongada
BRPI0919116A2 (pt) método
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
CO6781493A2 (es) Inhibidores de la faah
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0919548A2 (pt) pacote para inserto
DK2313489T3 (da) Fremstillingsmetode
BR112014013614A2 (pt) composição antimicrobiana, método para desinfetar uma superfície e uso de uma composição
BRPI0918955A2 (pt) preparação sólida, e, método para estabilizar um composto, e para melhorar a dissoulução de um composto
BR112013009590A2 (pt) composto, composição fungicida e método
BR112014013601A8 (pt) composição antimicrobiana sólida, método para desinfetar uma superfície e uso de uma composição
BRPI0916597A2 (pt) Método
BR112014012759A2 (pt) composto, composição e método para tratamento
BRPI0906868A2 (pt) Método para a preparação de uma composição lubrificante, e, composição lubrificante
BRPI0908497A2 (pt) métodos e composições para um rendimento aumentado
BRPI0918108A2 (pt) composição para tratamento, método de tratamento e uso de uma composição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.